SCHEMBL2956918

SCHEMBL2956918

NCCNC(=O)c1cc2cc3c4c(c2oc1=O)CCCN4CCC3

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC16A3 O15427 1/20 0.67
▸ ALDH1A1 P00352 8/20 0.52
▸ KMT2A Q03164 8/20 0.52
▸ USP2 O75604 7/20 0.52
▸ MEN1 O00255 7/20 0.52
▸ GAA P10253 4/20 0.52
▸ CASP1 P29466 4/20 0.52
▸ CASP7 P55210 4/20 0.52
▸ ALOX15 P16050 3/20 0.52
▸ LMNA P02545 3/20 0.52
▸ HSD17B10 Q99714 3/20 0.52
▸ BRCA1 P38398 2/20 0.52
▸ HBB P68871 2/20 0.52
▸ HTT P42858 2/20 0.52
▸ ATM Q13315 2/20 0.52
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ KDM4E B2RXH2 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18729881 0.90 SLC16A3 (0.59) SLC16A3ALDH1A1KMT2AUSP2MEN1
SCHEMBL18517777 0.89 SLC16A3 (0.66) SLC16A3ALDH1A1KMT2AUSP2MEN1
SCHEMBL13238317 0.89 SLC16A3 (0.69) SLC16A3ALDH1A1KMT2AUSP2MEN1
SCHEMBL2956917 0.88 SLC16A3 (0.67) SLC16A3ALDH1A1KMT2AUSP2MEN1
SCHEMBL16900679 0.87 SLC16A3 (0.70) SLC16A3ALDH1A1KMT2AUSP2MEN1
SCHEMBL23872036 0.87 SLC16A3 (0.67) SLC16A3ALDH1A1KMT2AUSP2MEN1
SCHEMBL13238299 0.85 SLC16A3 (0.64) SLC16A3ALDH1A1KMT2AUSP2MEN1
SCHEMBL23872035 0.84 SLC16A3 (0.60) SLC16A3ALDH1A1KMT2AUSP2MEN1
SCHEMBL26307770 0.84 SLC16A3 (0.74) SLC16A3ALDH1A1KMT2AUSP2MEN1
SCHEMBL13238296 0.83 SLC16A3 (0.58) SLC16A3ALDH1A1KMT2AUSP2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1842923-B1 Methanesulfonylaminoindole derivatives and labeled oligonucleotide probes containing them ROCHE DIAGNOSTICS GMBH (DE) 2015-07-15 — — EP disclosed
US-8623239-B2 Compound and functional luminescent probe comprising the same NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) 2014-01-07 — — US disclosed
US-8623239-B2 Compound and functional luminescent probe comprising the same NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) 2014-01-07 — — US disclosed
US-20110201802-A1 Novel Compound and Functional Luminescent Probe Comprising the Same NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) 2011-08-18 — — US disclosed
US-20110201802-A1 Novel Compound and Functional Luminescent Probe Comprising the Same NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) 2011-08-18 — — US disclosed
EP-2348314-A1 NOVEL COMPOUND AND FUNCTIONAL LUMINESCENT PROBE COMPRISING SAME National University Corporation Gunma University (JP) 2011-07-27 — — EP disclosed
US-7759470-B2 Labeling reagent ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2010-07-20 — — US disclosed
US-20070196852-A1 Labeling reagent ROCHE DIAGNOSTICS GMBH (DE) 2007-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201802-A1 Novel Compound and Functional Luminescent Probe Comprising the Same PPOX, PPIP5K2, DUOX2 SLC16A3 1163/4885ALDH1A1 3570/4885KMT2A 3171/4885
US-20070196852-A1 Labeling reagent INMT, RNGTT, DUT SLC16A3 1443/4885ALDH1A1 458/4885KMT2A 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback